A Nielsen Holdings PLC executive spoke at a conference about how proposed Treasury Department tax rules could raise the company's tax rate. A Business News article Thursday about the rules incorrectly implied the company has raised its concerns with the U.S. government.

The wholesale acquisition cost of the prostate cancer drug Xtandi, marketed by Astellas Pharma Inc. of Japan and Medivation Inc., is about $9,400 a month, compared with about $8,600 for rival drug Zytiga from Johnson & Johnson. A Business News article Thursday about a test that can identify patients unlikely to benefit from either drug quoted Xtandi's price as more than $10,000, using the average wholesale price, which is higher than the wholesale acquisition cost.

(END) Dow Jones Newswires

July 09, 2016 02:47 ET (06:47 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Astellas Pharma (PK) (USOTC:ALPMY)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Astellas Pharma (PK) Charts.
Astellas Pharma (PK) (USOTC:ALPMY)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Astellas Pharma (PK) Charts.